Patents by Inventor Florence Medaisko
Florence Medaisko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8119687Abstract: A compound corresponding to general formula (I): in which R1 represents a phenyl or naphthalenyl group optionally substituted with one or more halogen atoms or hydroxyl, cyano, nitro, (C1-C3)alkyl, (C1-C3)alkoxy, trifluoromethyl, trifluoromethoxy, benzyloxy, (C3-C6)cycloalkyl-O— or (C3-C6)cycloalkyl(C1-C3)alkoxy groups; R2 represents either a group of general formula CHR3CONHR4 in which R3 represents a hydrogen atom or a methyl group and R4 represents a hydrogen atom or a (C1-C3)alkyl, (C3-C5) cycloalkyl or (pyridin-4-yl)methyl group; or a 2,2,2-trifluoroethyl group; or an (imidazol-2-yl)methyl group; or a (benzimidazol-2-yl)methyl group; or a phenyl group optionally substituted with one or more halogen atoms or cyano, nitro, (C1-C3)alkyl, (C1-C3)alkoxy, trifluoromethyl or trifluoromethoxy groups; and n represents a number ranging from 1 to 3; in the form of a base, of an addition salt with an acid, of a hydrate or of a solvate.Type: GrantFiled: July 12, 2010Date of Patent: February 21, 2012Assignee: Sanofi-AventisInventors: Ahmed Abouabdellah, Michele Bas, Gihad Dargazanli, Christian Hoornaert, Adrien Tak Li, Florence Medaisko
-
Publication number: 20120029027Abstract: The invention relates to a compound of the general formula (I), where: R is a hydrogen atom or a group selected from the (C1-C6)alkyl or (C3-C7)-cycloalkyl groups, optionally substituted by one or more groups independently selected from a halogen atom anti the (C3-C7)-cycloalkyl, (C1-C6)alkyl, (C1-C6)alkoxy, and hydroxy groups; R1 is a phenyl group optionally substituted by one or more substituents independently selected from halogen atoms and the (C1-C6)alkyl, (C1-C6)alkoxy, halo-(C1C6)alkyl, hydroxy, halo-(C1-C6)alkoxy, (C1-C6)alkyl-thio, (C1-C6)alkyl-SO, and (C1-C6)alkyl-SO2 groups; R2 is one or more substituents selected from a hydrogen atom, halogen atoms, and the halo-(C1-C6)alkyl, (C1-C6)alkyl, (C3-C7)cycloalkyl, (C3-C7)-cycloalkyl-(C1C3)alkyl, phenyl, benzyl, (C1-C6)alkoxy, (C1-C6)alkyl-thio, (C1-C6))alkyl-SO, and (C1-C6)alkyl-SO2 groups; and Het is a heteroaryl group; wherein said compound is in the form of a base or an acid addition salt.Type: ApplicationFiled: March 15, 2010Publication date: February 2, 2012Applicant: SANOFIInventors: Geneviève Estenne-Bouhtou, Florence Medaisko
-
Publication number: 20100280076Abstract: A compound corresponding to general formula (I): in which R1 represents a phenyl or naphthalenyl group optionally substituted with one or more halogen atoms or hydroxyl, cyano, nitro, (C1-C3)alkyl, (C1-C3)alkoxy, trifluoromethyl, trifluoromethoxy, benzyloxy, (C3-C6)cycloalkyl-O— or (C3-C6)cycloalkyl(C1-C3)alkoxy groups; R2 represents either a group of general formula CHR3CONHR4 in which R3 represents a hydrogen atom or a methyl group and R4 represents a hydrogen atom or a (C1-C3)alkyl, (C3-C5) cycloalkyl or (pyridin-4-yl)methyl group; or a 2,2,2-trifluoroethyl group; or an (imidazol-2-yl)methyl group; or a (benzimidazol-2-yl)methyl group; or a phenyl group optionally substituted with one or more halogen atoms or cyano, nitro, (C1-C3)alkyl, (C1-C3)alkoxy, trifluoromethyl or trifluoromethoxy groups; and n represents a number ranging from 1 to 3; in the form of a base, of an addition salt with an acid, of a hydrate or of a solvate.Type: ApplicationFiled: July 12, 2010Publication date: November 4, 2010Applicant: Sanofi-AventisInventors: Ahmed ABOUABDELLAH, Michele Bas, Gihad Dargazanli, Christian Hoornaert, Adrien Tak Li, Florence Medaisko
-
Publication number: 20100267766Abstract: The disclosure relates to a compound of formula (I): wherein m, n, Ar, and R are as defined in the disclosure, to compositions containing them and to their therapeutic use. The disclosure also relates to processes for preparing these compounds and to certain intermediate compounds.Type: ApplicationFiled: June 30, 2010Publication date: October 21, 2010Applicant: SANOFI-AVENTISInventors: Gihad Dargazanli, Genevieve Estenne-Bouhtou, Florence Medaisko, Maria-Carmen Renones
-
Patent number: 7777057Abstract: A compound corresponding to general formula (I): in which R1 represents a phenyl or naphthalenyl group optionally substituted with one or more halogen atoms or hydroxyl, cyano, nitro, (C1-C3)alkyl, (C1-C3)alkoxy, trifluoromethyl, trifluoromethoxy, benzyloxy, (C3-C6)cycloalkyl-O— or (C3-C6)cycloalkyl(C1-C3)alkoxy groups; R2 represents either a group of general formula CHR3CONHR4 in which R3 represents a hydrogen atom or a methyl group and R4 represents a hydrogen atom or a (C1-C3)alkyl, (C3-C5)cycloalkyl or (pyridin-4-yl)methyl group; or a 2,2,2-trifluoroethyl group; or an (imidazol-2-yl)methyl group; or a (benzimidazol-2-yl)methyl group; or a phenyl group optionally substituted with one or more halogen atoms or cyano, nitro, (C1-C3)alkyl, (C1-C3)alkoxy, trifluoromethyl or trifluoromethoxy groups; and n represents a number ranging from 1 to 3; in the form of a base, of an addition salt with an acid, of a hydrate or of a solvate.Type: GrantFiled: July 28, 2009Date of Patent: August 17, 2010Assignee: Sanofi-AventisInventors: Ahmed Abouabdellah, Michele Bas, Gihad Dargazanli, Christian Hoornaert, Adrien Tak Li, Florence Medaisko
-
Patent number: 7776880Abstract: The disclosure relates to a compound of formula (I): wherein m, n, Ar, and R are as defined in the disclosure, to compositions containing them and to their therapeutic use. The disclosure also relates to processes for preparing these compounds and to certain intermediate compounds.Type: GrantFiled: March 19, 2009Date of Patent: August 17, 2010Assignee: sanofi-aventisInventors: Gihad Dargazanli, Genevieve Estenne-Bouhtou, Florence Medaisko, Maria-Carmen Renones
-
Patent number: 7700585Abstract: Compounds of formula (I) as defined herein: are useful for treating behavioral disorders associated with dementia, psychoses, in particular schizophrenia (deficient form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics; for the treatment of various forms of anxiety, panic attacks, phobias, and compulsive obsessive disorders; for treating various forms of depression, including psychotic depression; for treating disorders caused by alcohol abuse or weaning from alcohol, sexual behavior disorders, eating disorders and for treating migraine.Type: GrantFiled: April 30, 2007Date of Patent: April 20, 2010Assignee: sanofi-aventisInventors: Gihad Dargazanli, Genevieve Estenne-Bouhtou, Florence Medaisko, Nathalie Rakotoarisoa
-
Publication number: 20090286868Abstract: A compound corresponding to general formula (I): in which R1 represents a phenyl or naphthalenyl group optionally substituted with one or more halogen atoms or hydroxyl, cyano, nitro, (C1-C3)alkyl, (C1-C3)alkoxy, trifluoromethyl, trifluoromethoxy, benzyloxy, (C3-C6)cycloalkyl-O— or (C3-C6)cycloalkyl(C1-C3)alkoxy groups; R2 represents either a group of general formula CHR3CONHR4 in which R3 represents a hydrogen atom or a methyl group and R4 represents a hydrogen atom or a (C1-C3)alkyl, (C3-C5)cycloalkyl or (pyridin-4-yl)methyl group; or a 2,2,2-trifluoroethyl group; or an (imidazol-2-yl)methyl group; or a (benzimidazol-2-yl)methyl group; or a phenyl group optionally substituted with one or more halogen atoms or cyano, nitro, (C1-C3)alkyl, (C1-C3)alkoxy, trifluoromethyl or trifluoromethoxy groups; and n represents a number ranging from 1 to 3; in the form of a base, of an addition salt with an acid, of a hydrate or of a solvate.Type: ApplicationFiled: July 28, 2009Publication date: November 19, 2009Applicant: Sanofi-AventisInventors: Ahmed Abouabdellah, Michele Bas, Gihad Dargazanli, Christian Hoornaert, Adrien Tak Li, Florence Medaisko
-
Publication number: 20090258899Abstract: The disclosure relates to a compound of formula (I): wherein m, n, Ar, and R are as defined in the disclosure, to compositions containing them and to their therapeutic use. The disclosure also relates to processes for preparing these compounds and to certain intermediate compounds.Type: ApplicationFiled: March 19, 2009Publication date: October 15, 2009Applicant: SANOFI-AVENTISInventors: Gihad DARGAZANLI, Genevieve ESTENNE-BOUHTOU, Florence MEDAISKO, Maria-Carmen RENONES
-
Patent number: 7335670Abstract: Compounds of formula (I) as defined herein: are useful for treating behavioral disorders associated with dementia, psychoses, in particular schizophrenia (deficient form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics; for the treatment of various forms of anxiety, panic attacks, phobias, and compulsive obsessive disorders; for treating various forms of depression, including psychotic depression; for treating disorders caused by alcohol abuse or weaning from alcohol, sexual behavior disorders, eating disorders and for treating migraine.Type: GrantFiled: April 17, 2006Date of Patent: February 26, 2008Assignee: Sanofi-AventisInventors: Gihad Dargazanli, Genevieve Estenne-Bouhtou, Florence Medaisko, Maria-Carmen Renones
-
Patent number: 7326722Abstract: The present invention discloses and claims a compound of general formula (I) wherein A, X and R2 are as described herein. Also disclosed and claimed is application of this compound in a variety of therapeutic applications.Type: GrantFiled: April 17, 2003Date of Patent: February 5, 2008Assignee: Sanofi-AventisInventors: Gihad Dargazanli, Geneviève Estenne-Bouhtou, Pascale Magat, Benoît Marabout, Florence Medaisko, Pierre Roger, Mireille Sevrin, Corinne Veronique
-
Publication number: 20070208006Abstract: Compounds of formula (I) as defined herein: are useful for treating behavioral disorders associated with dementia, psychoses, in particular schizophrenia (deficient form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics; for the treatment of various forms of anxiety, panic attacks, phobias, and compulsive obsessive disorders; for treating various forms of depression, including psychotic depression; for treating disorders caused by alcohol abuse or weaning from alcohol, sexual behavior disorders, eating disorders and for treating migraine.Type: ApplicationFiled: April 30, 2007Publication date: September 6, 2007Applicant: SANOFI-AVENTISInventors: Gihad DARGAZANLI, Genevieve ESTENNE-BOUHTOU, Florence MEDAISKO, Nathalie RAKOTOARISOA
-
Publication number: 20070197601Abstract: The present invention discloses and claims therapeutic use of a series of compounds of general formula (I) in which A, X and R2 are as described herein. Specifically, the compounds of formula (I) exhibit a particular activity as specific inhibitors of the glycine transporters glyt1 and/or glty2.Type: ApplicationFiled: April 3, 2007Publication date: August 23, 2007Applicant: SANOFI-AVENTISInventors: Gihad DARGAZANLI, Genevieve ESTENNE-BOUHTOU, Pascale MAGAT, Benoit MARABOUT, Florence MEDAISKO, Pierre ROGER, Mireille SEVRIN, Corinne VERONIQUE
-
Patent number: 7226917Abstract: Compounds of formula (I) as defined herein: are useful for treating behavioral disorders associated with dementia, psychoses, in particular schizophrenia (deficient form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics; for the treatment of various forms of anxiety, panic attacks, phobias, and compulsive obsessive disorders; for treating various forms of depression, including psychotic depression; for treating disorders caused by alcohol abuse or weaning from alcohol, sexual behavior disorders, eating disorders and for treating migraine.Type: GrantFiled: April 17, 2006Date of Patent: June 5, 2007Assignee: Sanofi-AventisInventors: Gihad Dargazanli, Genevieve Estenne-Bouhtou, Florence Medaisko, Nathalie Rakotoarisoa
-
Publication number: 20060247290Abstract: A compound corresponding to general formula (I): in which R1 represents a phenyl or naphthalenyl group optionally substituted with one or more halogen atoms or hydroxyl, cyano, nitro, (C1-C3) alkyl, (C1-C3) alkoxy, trifluoromethyl, trifluoromethoxy, benzyloxy, (C3-C6)cycloalkyl-O— or (C3-C6)cycloalkyl(C1-C3)alkoxy groups; R2 represents either a group of general formula CHR3CONHR4 in which R3 represents a hydrogen atom or a methyl group and R4 represents a hydrogen atom or a (C1-C3)alkyl, (C3-C5) cycloalkyl or (pyridin-4-yl)methyl group; or a 2,2,2-trifluoroethyl group; or an (imidazol-2-yl)methyl group; or a (benzimidazol-2-yl)methyl group; or a phenyl group optionally substituted with one or more halogen atoms or cyano, nitro, (C1-C3)alkyl, (C1-C3)alkoxy, trifluoromethyl or trifluoromethoxy groups; and n represents a number ranging from 1 to 3; in the form of a base, of an addition salt with an acid, of a hydrate or of a solvate.Type: ApplicationFiled: June 28, 2006Publication date: November 2, 2006Applicant: SANOFI-AVENTISInventors: Ahmed ABOUABDELLAH, Michele BAS, Gihad DARGAZANLI, Christian HOORNAERT, Adrien LI, Florence MEDAISKO
-
Patent number: 7119116Abstract: A compound corresponding to general formula (I): in which R1 represents a phenyl or naphthalenyl group optionally substituted with one or more halogen atoms or hydroxyl, cyano, nitro, (C1–C3)alkyl, (C1–C3)alkoxy, trifluoromethyl, trifluoromethoxy, benzyloxy, (C3–C6)cycloalkyl-O— or (C3–C6)cycloalkyl(C1–C3)alkoxy groups; R2 represents either a group of general formula CHR3CONHR4 in which R3 represents a hydrogen atom or a methyl group and R4 represents a hydrogen atom or a (C1–C3)alkyl, (C3–C5)cycloalkyl or (pyridin-4-yl)methyl group; or a 2,2,2-trifluoroethyl group; or an (imidazol-2-yl)methyl group; or a (benzimidazol-2-yl)methyl group; or a phenyl group optionally substituted with one or more halogen atoms or cyano, nitro, (C1–C3)alkyl, (C1–C3)alkoxy, trifluoromethyl or trifluoromethoxy groups; and n represents a number ranging from 1 to 3; in the form of a base, of an addition salt with an acid, of a hydrate or of a solvate.Type: GrantFiled: February 22, 2005Date of Patent: October 10, 2006Assignee: Sanofi-AventisInventors: Ahmed Abouabdellah, Michele Bas, Gihad Dargazanli, Christian Hoornaert, Adrien Tak Li, Florence Medaisko
-
Publication number: 20060223802Abstract: Compounds of formula (I) as defined herein: are useful for treating behavioral disorders associated with dementia, psychoses, in particular schizophrenia (deficient form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics; for the treatment of various forms of anxiety, panic attacks, phobias, and compulsive obsessive disorders; for treating various forms of depression, including psychotic depression; for treating disorders caused by alcohol abuse or weaning from alcohol, sexual behavior disorders, eating disorders and for treating migraine.Type: ApplicationFiled: April 17, 2006Publication date: October 5, 2006Applicant: Sanofi-aventisInventors: Gihad Dargazanli, Genevieve Estenne-Bouhtou, Florence Medaisko, Nathalie Rakotoarisoa
-
Publication number: 20060223886Abstract: Compounds of formula (I) as defined herein: are useful for treating behavioral disorders associated with dementia, psychoses, in particular schizophrenia (deficient form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics; for the treatment of various forms of anxiety, panic attacks, phobias, and compulsive obsessive disorders; for treating various forms of depression, including psychotic depression; for treating disorders caused by alcohol abuse or weaning from alcohol, sexual behavior disorders, eating disorders and for treating migraine.Type: ApplicationFiled: April 17, 2006Publication date: October 5, 2006Applicant: Sanofi-AventisInventors: Gihad Dargazanli, Genevieve Estenne-Bouhtou, Florence Medaisko, Maria-Carmen Renones
-
Publication number: 20050182130Abstract: A compound corresponding to general formula (I): in which R1 represents a phenyl or naphthalenyl group optionally substituted with one or more halogen atoms or hydroxyl, cyano, nitro, (C1-C3)alkyl, (C1-C3)alkoxy, trifluoromethyl, trifluoromethoxy, benzyloxy, (C3-C6)cycloalkyl—0— or (C3-C6)cycloalkyl(C1-C3)alkoxy groups; R2 represents either a group of general formula CHR3CONHR4 in which R3 represents a hydrogen atom or a methyl group and R4 represents a hydrogen atom or a (C1-C3)alkyl, (C3-C5)cycloalkyl or (pyridin-4-yl)methyl group; or a 2,2,2-trifluoroethyl group; or an (imidazol-2-yl)methyl group; or a (benzimidazol-2-yl)methyl group; or a phenyl group optionally substituted with one or more halogen atoms or cyano, nitro, (C1-C3)alkyl, (C1-C3)alkoxy, trifluoromethyl or trifluoromethoxy groups; and n represents a number ranging from 1 to 3; in the form of a base, of an addition salt with an acid, of a hydrate or of a solvate.Type: ApplicationFiled: February 22, 2005Publication date: August 18, 2005Applicant: Sanofi AventisInventors: Ahmed Abouabdellah, Michele Bas, Gihad Dargazanli, Christian Hoornaert, Adrien Li, Florence Medaisko
-
Publication number: 20050159450Abstract: Compound of general formula (I) in which A represents either a group of formula N—R1 in which R1 represents a hydrogen atom, an alkyl group, a cycloalkyl group, a phenylalkyl group, an alkenyl group or an alkynyl group, or a group of formula N+(O?)R1 in which R1 is as defined above, or alternatively a group of formula N+(R?)R1 in which R? represents an alkyl group and R1 is as defined above, X represents a hydrogen atom or one or more substituents chosen from halogen atoms and trifluoromethyl, alkyl and alkoxy groups, R2 represents a hydrogen atom, one or more substituents chosen from halogen atoms and trifluoromethyl, alkyl and alkoxy groups, amino groups of formula NR3R4 in which R3 and R4 each represent a hydrogen atom or an alkyl group, or form with the nitrogen atom carrying them a pyrrolidine, piperidine or morpholine ring, or an optionally substituted phenyl group. Application in therapy.Type: ApplicationFiled: April 17, 2003Publication date: July 21, 2005Inventors: Gihad Dargazanli, Genevieve Estenne-Bouhtou, Pascale Magat, Benoit Marabout, Florence Medaisko, Pierre Roger, Mireille Sevrin, Corinne Veronique